VTGN has been in the news 321% more than usual
Feb 25, 2026, 3:34 PM
8.72%
What does VTGN do
VistaGen Therapeutics, a biopharmaceutical company based in South San Francisco, develops treatments for anxiety and depression using intranasal pherines and other therapies targeting central nervous system disorders. The company’s pipeline includes five clinical-stage investigational agents and went public on October 18, 2010.
VTGN has been in the news recently: Vistagen Therapeutics, Inc. is facing a class action lawsuit filed by Levi & Korsinsky, LLP on behalf of shareholders who experienced an 80% decline in stock value due to disappointing clinical trial results. The law firm is also investigating potential securities violations related to misleading statements made by the company prior to a deadline on March 16, 2026.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.